Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  SCYNEXIS, Inc.    SCYX

SCYNEXIS, INC.

(SCYX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2019 10/14/2019 10/15/2019 10/16/2019 10/17/2019 Date
1.04(c) 1.05(c) 1.1(c) 1.08(c) 1.14 Last
423 391 277 079 518 328 400 861 342 870 Volume
+2.97% +0.96% +4.76% -1.82% +5.56% Change
More quotes
Financials (USD)
Sales 2019 0,21 M
EBIT 2019 -47,1 M
Net income 2019 -55,0 M
Debt 2019 -
Yield 2019 -
Sales 2020 0,55 M
EBIT 2020 -44,9 M
Net income 2020 -46,3 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -1,08x
P/E ratio 2020 -1,56x
Capi. / Sales2019 291x
Capi. / Sales2020 110x
Capitalization 60,2 M
More Financials
Company
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078... 
Sector
Pharmaceuticals
Calendar
11/14Earnings Release
More about the company
Surperformance© ratings of SCYNEXIS, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SCYNEXIS, INC.
10/10SCYNEXIS : to Strengthen its Balance Sheet with Non-Dilutive Funding Through the..
PR
10/03SCYNEXIS : to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medi..
AQ
10/02SCYNEXIS : to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medi..
PR
10/01SCYNEXIS : Antimicrobials Working Group Highlights Member Company Participation ..
PR
09/19SCYNEXIS : Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phas..
AQ
09/18SCYNEXIS : Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phas..
PR
09/04SCYNEXIS, INC. : to Participate in Two Upcoming Investor Conferences
PR
08/08SCYNEXIS : Reports Second Quarter 2019 Financial Results and Provides Company Up..
AQ
08/07SCYNEXIS : 2Q Earnings Snapshot
AQ
08/07SCYNEXIS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
07/31SCYNEXIS, INC. : to Present at the 39th Annual Canaccord Genuity Global Growth C..
PR
07/25SCYNEXIS : Announces Special Protocol Assessment Agreement with FDA for Phase 3 ..
AQ
07/24SCYNEXIS : Announces Special Protocol Assessment (SPA) Agreement with FDA for Ph..
PR
07/01SCYNEXIS : X-Biotix Therapeutics Joins Antimicrobials Working Group
PR
06/26SCYNEXIS : World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp..
AQ
More news
News in other languages on SCYNEXIS, INC.
2014SCYNEXIS : annonce le prix de son action pour son premier appel public à l'éparg..
2014SCYNEXIS : gibt Kurspreis der Aktienemission bekannt
More news
Sector news : Pharmaceuticals - NEC
05:25aTeva to donate over $15 billion worth of drugs in opioid settlement - source
RE
02:49aJOHNSON & JOHNSON : J&J Seeks $4 Billion Opioid Settlement
DJ
10/16DRUG FIRMS OFFER TO SETTLE U.S. OPIO : sources
RE
10/16JOHNSON & JOHNSON : J&J Offers $4 Billion Opioid Litigation Settlement
DJ
10/16Johnson & Johnson Shares Rise
DJ
More sector news : Pharmaceuticals - NEC
Chart SCYNEXIS, INC.
Duration : Period :
SCYNEXIS, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCYNEXIS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 4,58  $
Last Close Price 1,08  $
Spread / Highest target 456%
Spread / Average Target 324%
Spread / Lowest Target 178%
EPS Revisions
Managers
NameTitle
Marco Taglietti President, Chief Executive Officer & Director
Guy MacDonald Chairman
Eric Francois Chief Financial Officer
David Angulo Gonzalez Chief Medical Officer
Ann F. Hanham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SCYNEXIS, INC.124.21%60
JOHNSON & JOHNSON2.94%356 736
ROCHE HOLDING AG17.38%245 163
MERCK AND COMPANY10.52%216 224
PFIZER-16.75%200 998
NOVARTIS16.30%198 756